A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.

This study has been completed.

Study NCT00423566 Information provided by University of Oxford

First Received: January 17, 2007 No Changes Posted

No Study Results Posted for this Study

Study Status:	This study has been completed.
Estimated Study Completion Date:	July 2003
Estimated Primary Completion Date:	No date given